2023
Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease
Hanna J, Smolderen K, Castro‐Dominguez Y, Romain G, Lee M, Turner J, Mena‐Hurtado C. Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Journal Of The American Heart Association 2023, 12: e028622. PMID: 36974774, PMCID: PMC10122876, DOI: 10.1161/jaha.122.028622.Peer-Reviewed Original ResearchConceptsEarly-stage chronic kidney diseaseChronic kidney diseaseBare metal stentsDrug-eluting stentsDrug-coated balloonsMortality riskAmputation riskKidney diseaseSevere chronic kidney diseaseMajor amputation riskPlain balloon angioplastyDrug-Coated BalloonAmputation outcomesCKD statusAmputation rateCause mortalityBackground PatientsAdjusted analysisBalloon angioplastyFemoropopliteal interventionsDES useBMS useRegistry dataDisease trialsPatientsUse of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease
Castro-Dominguez Y, Smolderen K, Romain G, Turner J, Mena-Hurtado C. Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease. Vascular Medicine 2023, 28: 150-152. PMID: 36710497, DOI: 10.1177/1358863x221148521.Peer-Reviewed Original Research
2022
Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions
Castro-Dominguez Y, Smolderen KG, Pichert M, Alabi O, Romain G, Huang J, Lee M, Ahmed Z, Peri-Okonny PA, Arham A, Brice A, Chaar CO, Stacy MR, Mena-Hurtado C. Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions. Journal Of Vascular Surgery 2022, 76: 1675-1680. PMID: 35868423, DOI: 10.1016/j.jvs.2022.06.093.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsDrug-eluting stentsBare metal stentsDES useFemoropopliteal endovascular interventionEndovascular interventionMedian odds ratioFemoropopliteal diseaseLesion characteristicsPrimary treatmentChronic kidney disease stage 4Adjusted median odds ratioVascular Quality Initiative registryAppropriate use guidelinesPrior anticoagulant usePatient-level factorsPoor functional statusTrans-Atlantic InterPlain balloon angioplastyPatient-level characteristicsFavorable patency ratesHierarchical logistic regression modelsLogistic regression modelsMeta-analysis publicationsRutherford classification
2021
Trends in drug-coated device use for peripheral artery disease: Insights from the Vascular Quality Initiative (VQI)
Pichert MD, Smolderen KG, Castro-Dominguez Y, Jelani QU, Nagpal S, Provance JB, Huang J, Malik AO, Secemsky EA, Derbas LA, Mena-Hurtado CI. Trends in drug-coated device use for peripheral artery disease: Insights from the Vascular Quality Initiative (VQI). Vascular Medicine 2021, 27: 73-74. PMID: 34610776, DOI: 10.1177/1358863x211043567.Peer-Reviewed Original Research
2011
Percutaneous transluminal angioplasty: Association between depressive symptoms and diminished health status benefits
Smolderen KG, Safley DM, House JA, Spertus JA, Marso SP. Percutaneous transluminal angioplasty: Association between depressive symptoms and diminished health status benefits. Vascular Medicine 2011, 16: 260-266. PMID: 21828173, DOI: 10.1177/1358863x11415568.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonCross-Sectional StudiesDepressionFemaleHealth StatusHumansLinear ModelsMaleMiddle AgedMissouriPatient SatisfactionPeripheral Arterial DiseaseProspective StudiesQuality of LifeRecovery of FunctionRegistriesRisk AssessmentRisk FactorsSeverity of Illness IndexSocial BehaviorSurveys and QuestionnairesTime FactorsTreatment OutcomeConceptsPeripheral artery diseasePeripheral endovascular revascularizationPercutaneous transluminal angioplastyDepressive symptomsHealth statusWorsened depressionHealth status 1 yearDisease-specific health statusHealth status benefitsBaseline depressive symptomsHealth status outcomesEndovascular revascularizationPAD patientsTransluminal angioplastyArtery diseaseDepression statusCardiac diseasePatientsStatus outcomesSymptomsLess improvementDepressionBaselineStatus benefitsDisease